Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders ; volume:28 ; number:9 ; day:21 ; month:7 ; year:2023 ; pages:3709-3716 ; date:9.2023
Molecular psychiatry ; 28, Heft 9 (21.7.2023), 3709-3716, 9.2023
- Urheber
-
Boyer, Laurent
Falissard, Bruno
Nuss, Philippe
Collin, Cedric
Duret, Stephanie
Rabbani, Marc
Chefdebien, Isabelle De
Tonelli, Isabelle
Llorca, Pierre Michel
Fond, Guillaume
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41380-023-02175-z
- URN
-
urn:nbn:de:101:1-2024030321174183411983
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Boyer, Laurent
- Falissard, Bruno
- Nuss, Philippe
- Collin, Cedric
- Duret, Stephanie
- Rabbani, Marc
- Chefdebien, Isabelle De
- Tonelli, Isabelle
- Llorca, Pierre Michel
- Fond, Guillaume
- SpringerLink (Online service)
Ähnliche Objekte (12)
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors